Project Grant R56HL174836
Award Date
9/24/24
Completion Date
8/31/25
Dollars Obligated
$812K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $2,290,407.00 to the University of Utah to advance the use of radiation as a non-invasive means of cardiac arrhythmia ablation. The key objectives are to: (1) determine the dose response and structural/functional effects of radiation on cardiac tissue; (2) create radiation targeting strategies using personalized computational models of ventricular...
This $810,964 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, supports the development of a novel non-invasive 3D mapping technique to accurately identify the site of origin for ventricular tachycardia (VT) and premature ventricular complexes (PVCs) using 12-lead ECG data. The project aims to create a computerized method that can automatically locate the VT exit/PVC origin site in real-time,...
This Project Grant award of $760,982.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at the University of Texas MD Anderson Cancer Center to investigate the role of the enzyme GFPT2 in radiation-induced cardiovascular disease. The key objectives are to elucidate how radiation-induced telomeric DNA damage and subsequent signaling pathways lead to GFPT2 acetylation and stabilization, thereby promoting glutamate metabolism and...
The federal Project Grant award of $620,371, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research to determine the voltage-sensing domain (VSD) dynamics of cardiac ion channels from the CNBD family, which play a pivotal role in regulating the electrical properties of the heart. The overarching objective is to leverage advanced biophysical techniques, including patch-clamp fluorometry, transition...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,137,498 to The Trustees of the University of Pennsylvania to conduct research on cardiac maturation. The project aims to: 1) investigate the role of naturally-occurring variants in human cardiomyocyte genomic estrogen-related receptor (ERR) binding sites and their contribution to heart disease; 2) assess the potential of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $317,285 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Rithim Biologics Inc. to develop a novel gene therapy approach to prevent ventricular tachycardia (VT) following a myocardial infarction. The project aims to finalize the development of an epicardial gene painting catheter, verify targeted ventricular gene expression, and evaluate the safety and efficacy of the gene therapy in a porcine...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $149,948 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University to investigate the role of p53 signaling in endothelial-to-mesenchymal transition and its impact on radiation-induced coronary heart disease. The 2-year project aims to utilize human-induced pluripotent stem cells and transgenic mouse models to elucidate the functional and molecular alterations in the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research aims to develop an integrated super-resolution cardiac magnetic resonance imaging and deep learning (CMR-DL) technology to isolate and quantify the contributions of passive and active remodeling events to left ventricular diastolic dysfunction (LVDD). The total award amount is $702,534, with a project period from March 6, 2025 to December 31, 2029. The awardee,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The goal is to reduce non-responder rates and improve patient identification for these treatments, especially for patients with...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $429,153 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Michigan Technological University. The funding supports research to improve patient selection and left ventricular lead placement for cardiac resynchronization therapy (CRT) by integrating analysis of electrical dyssynchrony on ECG and mechanical dyssynchrony on gated SPECT myocardial perfusion imaging. The project aims to use unsupervised...